Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X:
“Presidential ESMO26
HARMONi-GI1 in advanced BTC
Ivonescimab-GemCis vs Durva-Gemcis
- mOS: 14.9 vs. 12.1 months; HR 0.75, 95% CI 0.61-0.92, P = 0.0031
- mPFS: 8.4 vs. 5.8 months, HR 0.61, 95% CI 0.51-0.72, P <0.0001
- ORR: 53.8 % vs. 32.5 % (P <0.0001).”
You can also read: HARMONi-GI1 at ESMO 2026: Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer
